Targeting IgA Nephropathy: Insights into Pathogenesis, Novel Therapies, and Clinical Application
Key Takeaway: Treatment of IgA nephropathy has rapidly shifted toward mechanism-based, targeted therapies that address the 4-hit pathogenesis model; optimal care now requires integrating emerging evidence and updated guidelines to individualize use of traditional and novel agents to slow disease progression.
Learning Objectives:
-
Explain the 4 hit hypothesis of the pathogenesis of IgA nephropathy
-
Compare and contrast mechanism of action, side effects, and role in therapy for new treatments for IgA nephropathy (budesonide delayed release capsules, sparsentan, atrasentan, and iptacopan)
-
Describe evidence for new treatments for IgA nephropathy (budesonide delayed release capsules, sparsentan, atrasentan, and iptacopan)
-
Apply updated guideline to a patient case in choosing the appropriate treatment from either traditional or new targeted treatments, or a combination of traditional and new treatments
60 minutes
Disclosures:
The following planners and presenters have disclosed a financial relationship with an ineligible company:
-
Marisa Battistella, PharmD, Speaker's Bureau [Otsuka, Bayer.]
-
Dana Rizk, MD, Grants/Research Support Travere Therapeutics, Calliditas Therapeutics, Otsuka Pharmaceuticals, Vertex Pharmaceuticals, Vera Therapeutics, LaRoche, Novartis
Pharmaceuticals (Chinook Pharmaceuticals]), Consultant [Novartis Pharmaceuticals, George Clinical, Otsuka Pharmaceuticals, Calliditas Therapeutics, LaRoche, Vera Therapeutics, BioCryst, Chugai, Biogen, Timberlyne Therapeutics, Honorarium [Calliditas Therapeutics, Novartis Pharmaceuticals, Otsuka Pharmaceuticals, Vera Therapeutics, BioCryst, Argenx, Alpine Immune Science, GSK.] -
Calvin Meaney, PharmD, BCPS - Speaker's Bureau [GSK], Consultant [GSK]
There are no conflicts of interest or financial relationships with an ineligible company that have been disclosed by the rest of the planners and presenters of this learning activity.
All relevant financial relationships have been mitigated.
Accreditation Details
In support of improving patient care, this activity is planned and implemented by The National Center for Interprofessional Practice and Education Office of Interprofessional Continuing Professional Development (OICPD). The OICPD is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians: The National Center for Interprofessional Practice and Education designates this live activity for 1 hour AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with their participation.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
Nurses: Participants will be awarded 1 contact hour of credit for attendance in this module.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
Pharmacists: This activity is approved for 1 contact hour. UAN: JA4008105-9999-26-024-H01-P.
IPCE: This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credits for learning and change.